Abstract
In this study, a nonlinear quantitative structure-activity relationship model for the prediction of the IC50 of trisubstituted thiazoles as Cdc7 kinase inhibitors was developed by the gene expression programming (GEP). This model is based on five descriptors which were selected from the descriptors’ pool by heuristic method (HM). GEP rendered a good correlation between the experimental and predicted log (IC50) values with a correlation coefficient and a mean error of 0.85 and 0.22 for the training set, 0.84 and 0.39 for the testing set, respectively. The results indicate that this QSAR model has good predictive capability and it points to further optimization opportunities for Cdc7 kinase inhibitors.
Keywords: Gene expression programming, IC50, kinase inhibitors, quantitative structure activity relationship, cell division cycle 7, trisubstituted thiazoles.
Letters in Drug Design & Discovery
Title:Studies on the IC50 of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors
Volume: 13 Issue: 1
Author(s): Huazhen Yang, Xun Liu, Zhiling Ye, Fucheng Song, Lianhua Cui, Zhuang Yu, Hongzong Si and Honglin Zhai
Affiliation:
Keywords: Gene expression programming, IC50, kinase inhibitors, quantitative structure activity relationship, cell division cycle 7, trisubstituted thiazoles.
Abstract: In this study, a nonlinear quantitative structure-activity relationship model for the prediction of the IC50 of trisubstituted thiazoles as Cdc7 kinase inhibitors was developed by the gene expression programming (GEP). This model is based on five descriptors which were selected from the descriptors’ pool by heuristic method (HM). GEP rendered a good correlation between the experimental and predicted log (IC50) values with a correlation coefficient and a mean error of 0.85 and 0.22 for the training set, 0.84 and 0.39 for the testing set, respectively. The results indicate that this QSAR model has good predictive capability and it points to further optimization opportunities for Cdc7 kinase inhibitors.
Export Options
About this article
Cite this article as:
Yang Huazhen, Liu Xun, Ye Zhiling, Song Fucheng, Cui Lianhua, Yu Zhuang, Si Hongzong and Zhai Honglin, Studies on the IC50 of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors, Letters in Drug Design & Discovery 2016; 13 (1) . https://dx.doi.org/10.2174/1570180812999150713144215
DOI https://dx.doi.org/10.2174/1570180812999150713144215 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis
Current Cancer Drug Targets Synthetic Small Molecule Inhibitors of Hh Signaling As Anti-Cancer Chemotherapeutics
Current Medicinal Chemistry Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Hypoxia and Oxidative Stress in the Pathogenesis of Gynecological Cancers and in Therapeutical Options
Current Cancer Therapy Reviews MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design Nucleosides, a Valuable Chemical Marker for Quality Control in Traditional Chinese Medicine Cordyceps
Recent Patents on Biotechnology AGE-RAGE System and Carcinogenesis
Current Pharmaceutical Design Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Utilizing ICG Spectroscopical Properties for Real-Time Nanoparticle Release Quantification <i>In vitro</i> and <i>In vivo</i> in Imaging Setups
Current Pharmaceutical Design Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Lipid Nucleoside Conjugates for the Treatment of Cancer
Current Pharmaceutical Design Editorial: Head and Neck Cancer: Recent Findings and New Targets
Current Topics in Medicinal Chemistry Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Interaction of Anthocyanins with Drug-metabolizing and Antioxidant Enzymes
Current Medicinal Chemistry Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers